Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 21, 2024 10:45am

118 Views

Post# 36049892

RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

May 21, 2024 -"The $80 billion figure is rare air. Last year, Johnson & Johnson was the lone company in the biopharma industry to top the mark with its $85.2 billion in sales, including contribtion from its medtech business."

[ I guess that the French company AstraZeneca is banking on taking their old (off-patent) Enhertu ADC technology to China for sale - which is how their intend to reach the US$80 Billion annual revenue target ]

https://www.fiercepharma.com/pharma/astrazeneca-fast-track-growth-sets-target-revenue-80b-2030

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali